Levosimendan

Generic Name: Levosimendan

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₂N_₆O

CAS Number: 141505-33-1

Unique Ingredient Identifier: C6T4514L4E

Background: Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Indication: For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.

Associated Conditions: Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure

Associated Therapies: Positive cardiac inotropic effect, Intravenous inotropic therapy

Clinical Trials

Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions

Not Applicable

Withdrawn

Conditions: Myocardial Infarction
Outcome

Interventions: Drug: Levosimendan

First Posted Date: 2017-01-18

Last Posted Date: 2022-10-27

Lead Sponsor: RWTH Aachen University

Registration Number: NCT03022877

Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure

Conditions: Heart Decompensation

First Posted Date: 2016-11-25

Last Posted Date: 2018-05-16

Lead Sponsor: Tenax Therapeutics, Inc.

Registration Number: NCT02973620

Preoperative levosimendán and Hip Fracture

Completed

Conditions: Hip Fracture
Ventricular Dysfunction, Left

Interventions: Drug: Levosimendan

First Posted Date: 2016-11-25

Last Posted Date: 2020-02-05

Lead Sponsor: Hospital Universitario de Canarias

Target Recruit Count: 19

Registration Number: NCT02972918

Locations: 🇪🇸
Complejo Hospitalario Universitario de Canarias, La Laguna, S/C Tenerife, Spain

Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock

Not Applicable

Conditions: Septic Shock

Interventions: Device: Microdialysis Probe (Muscle microdialysis)
Drug: Levosimendan
Drug: Dobutamine

First Posted Date: 2016-11-15

Last Posted Date: 2018-02-12

Lead Sponsor: Military Hospital of Tunis

Target Recruit Count: 50

Registration Number: NCT02963454

Locations: 🇹🇳
Military Hopital of Tunis, Tunis, Tunisia

Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock

Phase 4

Conditions: Septic Shock
Cardiomyopathy

Interventions: Drug: Norepinephrine
Drug: Levosimendan
Drug: Milrinone

First Posted Date: 2015-12-29

Last Posted Date: 2018-11-29

Lead Sponsor: Sahlgrenska University Hospital, Sweden

Target Recruit Count: 30

Registration Number: NCT02640846

Locations: 🇸🇪
Central intensivvårdsavdelning Sahlgrenska University Hospital, Gothenburg, Västra Götaland, Sweden

Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery

Phase 4

Completed

Conditions: Renal Insufficiency, Acute
Acute Kidney Injury

Interventions: Drug: Placebo
Drug: Levosimendan

First Posted Date: 2015-08-24

Last Posted Date: 2021-03-18

Lead Sponsor: Sahlgrenska University Hospital, Sweden

Target Recruit Count: 30

Registration Number: NCT02531724

Locations: 🇸🇪
Department of thoracic anesthesia, Sahlgrenska University Hospital, Gothenburg, Sweden

Changes in Cardiac Deformation Following Physiologic Alterations and Inotropic Support.

Not Applicable

Completed

Conditions: Physiology
Aortic Valve Stenosis
Heart Failure, Diastolic
Monitoring, Physiologic

Interventions: Drug: Levosimendan
Drug: Milrinone

First Posted Date: 2015-04-03

Last Posted Date: 2017-05-09

Lead Sponsor: Sahlgrenska University Hospital, Sweden

Target Recruit Count: 30

Registration Number: NCT02408003

Locations: 🇸🇪
Thoraxoperation/TIVA, Sahlgrenska universitetssjukhuset, Göteborg, Sweden

Levosimendan Administration and Outcome in Cardiac Surgery

Completed

Conditions: Treatment of Left Heart Insufficiency in an Operative Setting of Cardiac Surgery

Interventions: Drug: Levosimendan

First Posted Date: 2014-10-27

Last Posted Date: 2014-10-27

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 159

Registration Number: NCT02275013

Locations: 🇩🇪
Charité University Medicine, Berlin, Germany

Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Levosimendan

First Posted Date: 2014-10-10

Last Posted Date: 2015-11-06

Lead Sponsor: Centro Cardiologico Monzino

Target Recruit Count: 42

Registration Number: NCT02261948

Locations: 🇮🇹
Centro Cardiologico Monzino, Milano, MI, Italy

Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease?

Phase 2

Completed

Conditions: Congenital Heart Defects

Interventions: Drug: Milrinone
Drug: Levosimendan

First Posted Date: 2014-09-05

Last Posted Date: 2024-03-26

Lead Sponsor: Göteborg University

Target Recruit Count: 72

Registration Number: NCT02232399

Locations: 🇫🇮
Children´s Hospital, Helsinki University Central Hospital, Helsinki, Finland
🇸🇪
Queen Silvia Children´s Hospital, Göteborg, Västra Götaland, Sweden

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy